Dengvaxia presentationADVERTISEMENTTriomphe said Sanofi representatives made a presentation on the company’s pipeline products, including the Dengvaxia vaccine that at the time had been submitted for registration in the Philippines. “We discussed Dengvaxia vaccine in the meeting, knowing that Dengvaxia had been submitted for registration,” Triomphe said. Presentation“It was a question of presenting the pipeline of Sanofi, including Dengvaxia vaccine,” he said, adding that similar presentations were made in many other countries to show the efficacy and safety of the vaccine. ADVERTISEMENTThe statement was about the Dengvaxia vaccine making symptoms worse in vaccinated people who had not been previously exposed to the dengue virus. Grade 3 dengue symptoms refer to “moderate to severe” cases, Duque explained.

Source: Philippine Daily Inquirer December 13, 2017 20:15 UTC